Table 2.
Top canonical pathways identified at baseline (PRE) and on-treatment (POST) and their association with relapse free survival (RFS), disease non-progression (NP) and overall survival (OS).
| Pathways | PRE/RFS (Adjusted P) | PRE/NP (Adj. p) | POST/RFS (Adj. p) | POST/OS (Adj. p) |
|---|---|---|---|---|
| Antigen presentation | 0.0002 | 4.22 × 10−05 | 0.004 | 3.08 × 10−05 |
| Cytotoxic T lymphocyte-mediated apoptosis | 0.0004 | 3.92 × 10−07 | 0.004 | 0.0009 |
| T helper cell differentiation | 0.001 | 0.0005 | 0.05 | 0.023 |
| B cell development | 6.98 × 10−12 | 1.14 × 10−13 | 2.26 × 10−06 | 4.26 × 10−07 |
| iCOS-iCOSL signaling in T helper | 0.006 | 4.23 × 10−07 | 0.11 | 0.11 |
| OX40 signaling | 0.007 | 1.29 × 10−05 | 0.005 | 0.0002 |
| CD28 signaling in T helper cells | 0.04 | 8.3 × 10−05 | 0.04 | 0.15 |
| IL-4 signaling | 0.02 | 0.0008 | 0.06 | 0.002 |
| PKCθ signaling in T lymphocytes | 0.04 | 7.97 × 10−05 | 0.14 | 0.04 |
| Nur77 signaling in T lymphocytes | 0.03 | 0.0001 | 0.03 | 0.008 |
| SLE signaling | 1.52 × 10−05 | 4.27 × 10−06 | ||
| Allograft rejection signaling | 0.0003 | 4.27 × 10−06 | 0.004 | 0.0006 |
| Autoimmune thyroid signaling | 0.004 | 4.51 × 10−05 | 0.021 | 0.003 |